These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 31312105)

  • 21. Serum antimüllerian hormone/müllerian-inhibiting substance appears to be a more discriminatory marker of assisted reproductive technology outcome than follicle-stimulating hormone, inhibin B, or estradiol.
    Hazout A; Bouchard P; Seifer DB; Aussage P; Junca AM; Cohen-Bacrie P
    Fertil Steril; 2004 Nov; 82(5):1323-9. PubMed ID: 15533354
    [TBL] [Abstract][Full Text] [Related]  

  • 22. "Anti-Mullerian Hormone: Marker for Ovarian Response in Controlled Ovarian Stimulation for IVF Patients": A First Pilot Study in the Indian Population.
    Singh N; Malik E; Banerjee A; Chosdol K; Sreenivas V; Mittal S
    J Obstet Gynaecol India; 2013 Aug; 63(4):268-72. PubMed ID: 24431654
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy of three COS protocols and predictability of AMH and AFC in women with discordant ovarian reserve markers: a retrospective study on 19,239 patients.
    Guo Y; Jiang H; Hu S; Liu S; Li F; Jin L
    J Ovarian Res; 2021 Aug; 14(1):111. PubMed ID: 34454544
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Anti-Müllerian hormone for prediction of ovarian response in Chinese infertile women undergoing IVF/ICSI cycles: a prospective, multi-centre, observational study.
    Li R; Gong F; Zhu Y; Fang W; Yang J; Liu J; Hu L; Yang D; Liang X; Qiao J
    Reprod Biomed Online; 2016 Oct; 33(4):506-512. PubMed ID: 27502068
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Anti-Müllerian Hormone and Its Predictive Utility in Assisted Reproductive Technologies Outcomes.
    Granger E; Tal R
    Clin Obstet Gynecol; 2019 Jun; 62(2):238-256. PubMed ID: 30994481
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Low ovarian reserve and risk of miscarriage in pregnancies derived from assisted reproductive technology.
    Chinè A; Reschini M; Fornelli G; Basili L; Busnelli A; Viganò P; Muzii L; Somigliana E
    Hum Reprod Open; 2023; 2023(3):hoad026. PubMed ID: 37287447
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The addition of anti-Müllerian hormone in an algorithm for individualized hormone dosage did not improve the prediction of ovarian response-a randomized, controlled trial.
    Magnusson Å; Nilsson L; Oleröd G; Thurin-Kjellberg A; Bergh C
    Hum Reprod; 2017 Apr; 32(4):811-819. PubMed ID: 28175316
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Analysis of the women with the AMH concentrations below the limit of reference range but with the ideal number of retrieved oocytes.
    Wu W; Wang X; Li Y; Zhang Y
    Arch Gynecol Obstet; 2020 Apr; 301(4):1089-1094. PubMed ID: 32179967
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical value of serum anti-mullerian hormone and inhibin B in prediction of ovarian response in patients with polycystic ovary syndrome.
    Zhang F; Liu XL; Rong N; Huang XW
    J Huazhong Univ Sci Technolog Med Sci; 2017 Feb; 37(1):70-73. PubMed ID: 28224431
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Characterization of women with elevated antimüllerian hormone levels (AMH): correlation of AMH with polycystic ovarian syndrome phenotypes and assisted reproductive technology outcomes.
    Tal R; Seifer DB; Khanimov M; Malter HE; Grazi RV; Leader B
    Am J Obstet Gynecol; 2014 Jul; 211(1):59.e1-8. PubMed ID: 24593938
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Value of anti-Müllerian hormone in predicting pregnant outcomes of polycystic ovary syndrome patients undergone assisted reproductive technology].
    Li Y; Tan JQ; Mai ZY; Yang DZ
    Zhonghua Fu Chan Ke Za Zhi; 2018 Jan; 53(1):23-30. PubMed ID: 29374882
    [No Abstract]   [Full Text] [Related]  

  • 32. The use of anti-Müllerian hormone for controlled ovarian stimulation in assisted reproductive technology, fertility assessment and -counseling.
    Pilsgaard F; Grynnerup AG; Løssl K; Bungum L; Pinborg A
    Acta Obstet Gynecol Scand; 2018 Sep; 97(9):1105-1113. PubMed ID: 29476703
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Anti-Mullerian hormone-tailored stimulation protocols improve outcomes whilst reducing adverse effects and costs of IVF.
    Yates AP; Rustamov O; Roberts SA; Lim HY; Pemberton PW; Smith A; Nardo LG
    Hum Reprod; 2011 Sep; 26(9):2353-62. PubMed ID: 21672928
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Correlation of age and antimullerian hormone in assisted reproductive technology program outcome.
    Himabindu Y; Gopinathan KK; Pandey AK; Sriharibabu M
    Indian J Physiol Pharmacol; 2013; 57(1):9-15. PubMed ID: 24020093
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Oocyte matched follicular fluid anti-Müllerian hormone is an excellent predictor of live birth after fresh single embryo transfer.
    Ciepiela P; Dulęba AJ; Kario A; Chełstowski K; Branecka-Woźniak D; Kurzawa R
    Hum Reprod; 2019 Nov; 34(11):2244-2253. PubMed ID: 31725884
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Risk of severe ovarian hyperstimulation syndrome in GnRH antagonist versus GnRH agonist protocol: RCT including 1050 first IVF/ICSI cycles.
    Toftager M; Bogstad J; Bryndorf T; Løssl K; Roskær J; Holland T; Prætorius L; Zedeler A; Nilas L; Pinborg A
    Hum Reprod; 2016 Jun; 31(6):1253-64. PubMed ID: 27060174
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Factors affecting the distribution of serum anti-müllerian hormone levels among infertile Asian women: a multi-nation, multi-centre, and multi-ethnicity prospective cohort study.
    Tzeng CR; Huang Z; Asada Y; Zhang C; Ho MT; Li RHW; Kim JH; Govindarajan M; Vuyavanich T; Sini I; Wong PS; Singh S; Lin WY; Ho NT
    Hum Reprod; 2023 Jul; 38(7):1368-1378. PubMed ID: 37105234
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Anti-Mullerian hormone (AMH) as a predictive marker in assisted reproductive technology (ART).
    La Marca A; Sighinolfi G; Radi D; Argento C; Baraldi E; Artenisio AC; Stabile G; Volpe A
    Hum Reprod Update; 2010; 16(2):113-30. PubMed ID: 19793843
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Serum levels of anti-Müllerian hormone influence pregnancy outcomes associated with gonadotropin-releasing hormone antagonist treatment: a retrospective cohort study.
    Hou Y; Wang L; Li Y; Ai J; Tian L
    Sci Rep; 2023 Feb; 13(1):2127. PubMed ID: 36746984
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The role of anti-Müllerian hormone assessment in assisted reproductive technology outcome.
    Broer SL; Mol B; Dólleman M; Fauser BC; Broekmans FJ
    Curr Opin Obstet Gynecol; 2010 Jun; 22(3):193-201. PubMed ID: 20407372
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.